In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kindred Biosciences Inc. (NASDAQ:KIN) reported that Park West Asset Management has picked up 3,964,138 of common stock as of 2017-01-19.
The acquisition brings the aggregate amount owned by Park West Asset Management to a total of 3,964,138 representing a 19.9% stake in the company.
For those not familiar with the company, Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.
A glance at Kindred Biosciences Inc. (NASDAQ:KIN)’s key stats reveals a current market capitalization of 132.54 million based on 19.92 million shares outstanding and a price at last close of $6.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-13, Park picked up 1,690,000 at a purchase price of $6.20. This brings their total holding to 3,964,138 as of the date of the filing.
On the sell side, the most recent transaction saw Park unload 18,000 shares at a sale price of $4.78. This brings their total holding to 1,989,084.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kindred Biosciences Inc. (NASDAQ:KIN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
